VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag
Vaccine Information
  • Vaccine Name: HIV DNA vaccine Ad26/Ad5HVR48 encoding HIV or SIV env or gag
  • Target Pathogen: Human Immunodeficiency Virus
  • Target Disease: Acquired Immunodeficiency Syndrome (AIDS)
  • Vaccine Ontology ID: VO_0004342
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Human
  • env gene engineering:
    • Type: Recombinant vector construction
    • Description: This recombinant vector vaccine expressed env from HIV-1 (Barouch et al., 2012).
    • Detailed Gene Information: Click Here.
  • Gag from HIV 1 gene engineering:
    • Type: DNA vaccine construction
    • Description: This recombinant vector vaccine expressed gag from HIV-1 (Barouch et al., 2012).
    • Detailed Gene Information: Click Here.
  • env from SIV gene engineering:
    • Type: Recombinant vector construction
    • Description: This recombinant vector vaccine expressed env from SIV (Barouch et al., 2012).
    • Detailed Gene Information: Click Here.
  • Gag protein from SIV-mnd 2 gene engineering:
    • Type: DNA vaccine construction
    • Description: This recombinant vector vaccine expressed gag from SIV (Barouch et al., 2012).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Macaque Response

  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: After the high-dose vaginal SHIV-162P3 challenge, 7/8 control animals were infected. Similarly, 7/8 animals in the vaccine-only group (group V) were infected. In the microbicide-only group (group M), 4/8 animals were infected. In the combination group (group V+M), only 2/7 animals were infected. The intervention efficacy in group V+M was 67%. In summary, the data supports that vaccines and microbicides used in combination may confer protection against sexual HIV-1 transmission to women by the vaginal route (Barouch et al., 2012).
References
Barouch et al., 2012: Barouch DH, Klasse PJ, Dufour J, Veazey RS, Moore JP. Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(22); 8694-8698. [PubMed: 22586094].